Last updated: April 26, 2026
FLUCYTOSINE Suppliers: Who Makes It and What to Source
FLUCYTOSINE (also called flucytosine; marketed in several countries) is a generic sterile oral antifungal. Supplier coverage is typically split between: (1) API manufacturers that produce flucytosine for formulation houses, (2) finished-dose manufacturers that supply tablets/capsules to wholesalers, and (3) contract manufacturers that package and release finished products under private label or marketing authorization.
What supply categories exist for FLUCYTOSINE?
1) API (active pharmaceutical ingredient)
API supply is usually provided by chemical/fermentation specialty manufacturers with flucytosine lines or custom synthesis routes. API is commonly supplied with:
- CoA and typical impurity profile
- DMF/CEP or other regulatory traceability (varies by jurisdiction)
- Packaging suitable for formulation plants (drums or bulk bags, depending on site)
2) Finished product
Finished-dose supply typically covers:
- Solid oral dosage forms (tablets or capsules)
- Strengths that vary by market and regulatory label
- Compliance to local pharmacopeial standards (e.g., USP/BP/EP where applicable)
3) Packaging and distribution
Some companies do not produce API or finish manufacturing but distribute or repackage:
- Authorized wholesalers
- Contract packagers
- Private label distributors for national tender markets
Which suppliers exist by geography (practical sourcing map)
Europe
European distributors and wholesalers commonly source generic flucytosine through tender and hospital supply channels from EU finished-dose manufacturers and license holders. API is then imported into EU formulation plants from established API producers.
United Kingdom
UK supply often flows through wholesalers for finished-dose product, with API sourced for domestic formulation when demand supports local manufacturing.
United States
US availability depends on whether a manufacturer holds current ANDA or market authorization for the finished product. API import for formulation is typically from DMF-listed suppliers.
Asia (API and generic finished-dose)
Asia-based manufacturers are common sources for both API and finished products in generic markets, with distribution into Europe, Africa, and parts of LATAM via authorized channels.
Supplier short-list (actionable “who to contact” framework)
Because supplier identity depends on the exact market (EU vs US vs tender markets), dosage form, and current listing status, the correct way to build a procurement shortlist is to target three types of entities:
- API manufacturers with documented flucytosine production and impurity controls (CoA plus regulatory file linkage).
- Finished-dose generic manufacturers with flucytosine tablets/capsules at the target strength and local labeling.
- Authorized distributors/wholesalers that can provide chain-of-custody documentation and batch traceability for hospital or tender procurement.
What documents matter when qualifying a flucytosine supplier
For flucytosine, procurement teams typically require:
- Certificate of Analysis (CoA) for each batch (assay, impurities, water content if applicable)
- GMP certificate for the manufacturing site(s)
- Regulatory dossier link (DMF number, CEP, or local variation history depending on jurisdiction)
- Stability data aligned to shelf-life and storage conditions
- Packaging and labeling specs for the target market
Risk and supply continuity checks (what to verify before purchase)
1) Regulatory standing of the finished product
- Does the finished-dose product have active authorization in the destination country?
- Is supply steady or limited by batch release timing?
2) API traceability
- Can the API site provide CoA and full batch genealogy (API batch to finished product batch)?
- Are there recent changes in impurity profile or process?
3) Cold-chain is usually not required
Flucytosine oral solids typically ship under ambient conditions unless the specific product label specifies otherwise. Validate label storage conditions with the exact SKU.
Key Takeaways
- FLUCYTOSINE sourcing breaks into API suppliers, finished-dose manufacturers, and authorized distributors.
- Procurement success depends on regulatory authorization in the destination market and batch traceability from API through finished product release.
- Qualification should prioritize CoA-per-batch, GMP evidence, and regulatory file linkage (DMF/CEP/authorization history).
FAQs
1) Is flucytosine typically sourced as API or finished-dose?
Both models exist. Formulators source API; hospitals and tenders typically buy finished-dose tablets/capsules.
2) Do suppliers require GMP compliance?
Yes. GMP status applies at both the API and finished-dose manufacturing stages, with distributors expecting traceable batch release documentation.
3) What quality documents should buyers request?
CoA, GMP certificates, regulatory dossier linkages (DMF/CEP where applicable), and stability/label specifications for the target SKU.
4) Is the supply chain usually cold-chain dependent?
For standard oral solid products, cold-chain is usually not required. Confirm storage conditions from the specific product label.
5) How do buyers verify that a supplier can meet market authorization needs?
By confirming that the finished product is authorized in the destination country and by matching the API and finished-dose batch genealogy to release requirements.
References
[1] European Medicines Agency (EMA). European public assessment reports and product information (product authorization context).
[2] U.S. FDA. Drug Shortages database and FDA drug approval/ANDA resources (market availability context).
[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). GMP and quality guidance framework (qualification expectations).
